A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Status Recruiting

Clinical Trial Summary

The main aims of this study are to check for side effects from treatment with teduglutide (Revestive) and how well teduglutide controls symptoms of short bowel syndrome. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with short bowel syndrome will receive an injection of teduglutide just under the skin (subcutaneous) according to their clinic's standard practice. The study doctors will check for side effects from teduglutide for 36 months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05023382
Study type	Observational
Source	Takeda
Contact	Takeda Contact
Phone	+1-877-825-3327
Email	medinfoUS@takeda.com
Status	Recruiting
Phase
Start date	September 1, 2021
Completion date	July 31, 2030

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05635747` - A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB
Completed	`NCT01891279` - Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?	N/A
Completed	`NCT00930644` - Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)	Phase 3
Completed	`NCT01696656` - Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency	N/A
Completed	`NCT00910104` - Cholestasis Reversal: Efficacy of IV Fish Oil	Phase 2/Phase 3
Recruiting	`NCT04981262` - Improved Quality of Life in Children With Intestinal Failure	N/A
Completed	`NCT01930539` - Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp	N/A
Recruiting	`NCT04733066` - Quality of Life in Patients With Short Bowel Syndrome Treated Without and With Teduglutide - a Prospective Nested Matched Pair Analysis
Terminated	`NCT00742157` - Evaluate the Efficacy and Safety Growth Hormone, Glutamine and Diet in Patients With Short Bowel Syndrome (SBS)	Phase 4
Completed	`NCT04743960` - Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition	N/A
Completed	`NCT03690206` - Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)	Phase 3
Terminated	`NCT02266849` - Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study	Phase 3
Completed	`NCT01306838` - Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy	Early Phase 1
Completed	`NCT01380366` - rHGH and Intestinal Permeability in Intestinal Failure	Phase 4
Completed	`NCT00248573` - Mechanisms of Adaptation in Human Short Bowel Syndrome	Phase 1/Phase 2
Withdrawn	`NCT03371862` - Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)	Phase 2
Completed	`NCT04474743` - Malnutrition in Chronic Gastrointestinal Diseases, Cross-sectional Study
Completed	`NCT00067860` - Diet/Growth Factor Mechanisms of Gut Adaptation	Phase 2
Terminated	`NCT04046328` - Efficacy, Safety and Tolerability of Enteric-Coated Cholestyramine Capsules for Adult Short Bowel Syndrome	Phase 2
Completed	`NCT04877431` - A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease